Literature DB >> 21555614

Cost-effectiveness of 2 approaches to managing nasolacrimal duct obstruction in infants: the importance of the spontaneous resolution rate.

Kevin D Frick1, Luxme Hariharan, Michael X Repka, Danielle Chandler, B Michele Melia, Roy W Beck.   

Abstract

OBJECTIVE: To assess the impact of the rate of spontaneous resolution of congenital nasolacrimal duct obstruction on the relative cost-effectiveness of deferred nasolacrimal duct probing in a surgical facility (DFPS) compared with an immediate office-based probing surgery (IOPS).
METHODS: Data from the literature, Medicare 2009 fee schedule, and consensus assumptions were combined to populate a model of outcomes of 2 treatment strategies: immediate office-based probing (IOPS) and deferred facility-based probing (DFPS) (deferred for 6 months). Sensitivity analyses were conducted, varying the 6-month spontaneous resolution rate from 50% to 90%. Additional factors varied during analyses included surgical cost and each procedure's probability of success. Outcomes measured were overall cost of treatment, chance of cure, and months of symptoms avoided by 18 months of life.
RESULTS: Under the base case, assuming a 75% spontaneous resolution rate during 6 months prior to deferred probing, IOPS is more expensive ($771 vs $641) and slightly less effective (93.0% vs 97.5%) than DFPS, although IOPS costs only $44 per month of symptoms avoided. At spontaneous resolution rates between 50% and 68%, IOPS costs less than DFPS (from $2 to $342 less), although it also is slightly less effective (from 2.0% to 3.8% less). At a 90% spontaneous resolution rate, IOPS costs $169 per month of symptoms avoided. As the rate of spontaneous resolution falls, the cost per additional success for DFPS increases to $16 709 at a 50% spontaneous resolution rate.
CONCLUSION: The relative cost-effectiveness of these strategies for treatment of nasolacrimal duct obstruction depends on the spontaneous resolution rate after diagnosis.

Entities:  

Mesh:

Year:  2011        PMID: 21555614      PMCID: PMC3156092          DOI: 10.1001/archophthalmol.2011.80

Source DB:  PubMed          Journal:  Arch Ophthalmol        ISSN: 0003-9950


  8 in total

1.  Dacryostenosis.

Authors:  H W PRICE
Journal:  J Pediatr       Date:  1947-03       Impact factor: 4.406

2.  Primary treatment of nasolacrimal duct obstruction with probing in children younger than 4 years.

Authors:  Michael X Repka; Danielle L Chandler; Roy W Beck; Eric R Crouch; Sean Donahue; Jonathan M Holmes; Katherine Lee; Michele Melia; Graham E Quinn; Nick A Sala; Susan Schloff; David I Silbert; David K Wallace
Journal:  Ophthalmology       Date:  2007-11-08       Impact factor: 12.079

3.  Medical management of congenital nasolacrimal duct obstruction.

Authors:  L R Nelson; J H Calhoun; H Menduke
Journal:  Ophthalmology       Date:  1985-09       Impact factor: 12.079

4.  Balloon catheter dilation and nasolacrimal duct intubation for treatment of nasolacrimal duct obstruction after failed probing.

Authors:  Michael X Repka; Danielle L Chandler; Jonathan M Holmes; Darren L Hoover; Christine L Morse; Susan Schloff; David I Silbert; D Robbins Tien
Journal:  Arch Ophthalmol       Date:  2009-05

5.  Repeat probing for treatment of persistent nasolacrimal duct obstruction.

Authors:  Michael X Repka; Danielle L Chandler; Don L Bremer; Mary Louise Z Collins; Dave H Lee
Journal:  J AAPOS       Date:  2009-06       Impact factor: 1.220

Review 6.  Congenital nasolacrimal duct obstruction: natural history and the timing of optimal intervention.

Authors:  T O Paul; R Shepherd
Journal:  J Pediatr Ophthalmol Strabismus       Date:  1994 Nov-Dec       Impact factor: 1.402

7.  Medical management of congenital nasolacrimal duct obstruction.

Authors:  T O Paul
Journal:  J Pediatr Ophthalmol Strabismus       Date:  1985 Mar-Apr       Impact factor: 1.402

8.  The natural course of congenital obstruction of the nasolacrimal duct.

Authors:  R A Petersen; R M Robb
Journal:  J Pediatr Ophthalmol Strabismus       Date:  1978 Jul-Aug       Impact factor: 1.402

  8 in total
  2 in total

1.  A randomized trial comparing the cost-effectiveness of 2 approaches for treating unilateral nasolacrimal duct obstruction.

Authors: 
Journal:  Arch Ophthalmol       Date:  2012-12

2.  Success rates of probing for congenital nasolacrimal duct obstruction at various ages.

Authors:  Marta Świerczyńska; Ewelina Tobiczyk; Piotr Rodak; Dorota Barchanowska; Erita Filipek
Journal:  BMC Ophthalmol       Date:  2020-10-08       Impact factor: 2.209

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.